652-P: Real-World Effectiveness of Once-Weekly Semaglutide (sema OW) from a U.S. Commercially Insured and Medicare Advantage Population

Abstract

Background: This study presents real-world evidence on effectiveness of sema OW in a broad cohort of US commercially insured and Medicare Advantage T2D patients. Methods: Claims and lab result data were used to identify T2D patients who initiated sema OW between 12/1/17 - 6/30/20 (index as first claim). Selected patients had ≥1 A1c result within ≤3 months pre- and ≥3 months post-index. Patients persistent on sema OW (those with a sema OW prescription with days supply dispensed overlapping/in proximity of date of post-index A1c measurement) were assessed for A1c changes and stratified by age ( 9%. Results: 3,010 patients initiated sema OW, 49% were female and 10% were ≥ 65 years of age. A1c was significantly reduced vs. pre-index in all persistent patients (-1.1%) and in each age subgroup ( 9%. Attainment of A1c Conclusion: In this broad, real-world cohort of US T2D patients, initiation of sema OW was associated with significant reduction in A1c and an increase in reaching an A1c Disclosure V. Willey: Employee; Self; HealthCore. N. Shivappa: Other Relationship; Self; Novo Nordisk. J. Noone: Employee; Self; Novo Nordisk Inc. C. Swift: Employee; Self; Novo Nordisk Inc. S. Du: None. Y. M. Paprocki: Employee; Self; Novo Nordisk, Stock/Shareholder; Self; Novo Nordisk. H. Tan: Other Relationship; Self; HealthCore.